Table II.
Treatment patterns in PsO, PsA and PsO/PsA patients.
| Patients initiating etanercept (n = 2,534) |
Patients initiating adalimumab (n = 1,919) |
|||||
|---|---|---|---|---|---|---|
| PsO (n = 1,609) |
PsA (n = 679) |
PsO/PsA (n = 246) |
PsO (n = 1,166) |
PsA (n = 518) |
PsO/PsA (n = 235) |
|
| Initial dose of index therapy, n (%) <50 mg weekly 50 mg weekly 51–99 mg weekly 100 mg weekly 40 mg EOW >40 mg EOW to <40 mg weekly 40 mg weekly* >40 mg weekly |
33 (2.1) 417 (25.9) 253 (15.7) 906 (56.3) |
24 (3.5) 598 (88.1) 16 (2.4) 41 (6.0) |
7 (2.8) 162 (65.9) 16 (6.5) 61 (24.8) |
311 (26.7) 103 (8.8) 715 (61.3) 37 (3.2) |
468 (90.3) 7 (1.4) 40 (7.7) 3 (0.6) |
157 (66.8) 7 (3.0) 68 (28.9) 3 (1.3) |
| Pauses per patient†, mean no. (SD) | 2.1 (1.7)¶ | 2.0 (1.7) | 2.1 (1.8) | 1.9 (1.5) | 1.8 (1.7) | 1.9 (1.7) |
| Length of pause, mean days (SD) | 19.3 (28.5)¶ | 15.4 (22.9) | 15.8 (21.8) | 14.9 (24.2) | 14.0 (21.5) | 13.3 (20.5) |
| Longest pause, mean days (SD) | 43.2 (43.7)¶ | 34.2 (35.6) | 34.2 (33.3) | 34.7 (39.0) | 30.4 (34.0) | 29.0 (33.2) |
| Patients persistent on index medication for 12 months, n (%) | 746 (46.4) | 412 (60.7) | 143 (58.1) | 662 (56.8)¶ | 328 (63.3) | 140 (59.6) |
| Patients with 60-day gap‡, n (%) | 863 (53.6)¶ | 267 (39.3) | 103 (41.9) | 504 (43.2) | 190 (36.7) | 95 (40.4) |
| Time to switch, mean days (SD) | 199.9 (78.4)|| | 191.6 (79.4)§ | 189.7 (73.3) | 193.2 (81.2) | 178.9 (80.8) | 179.3 (77.3) |
| Total time on treatment on index medication, mean days (SD) | 305.0 (107.0) | 325.2 (99.8) | 321.4 (104.1) | 318.2 (105.2)¶ | 323.6 (104.0) | 311.4 (110.3) |
| Total treatment on switch medication, mean days (SD) | 321.0 (97.8) | 337.5 (91.5) | 339.3 (92.7) | 327.7 (99.3) | 338.7 (92.1) | 322.5 (104.1) |
*May be 80 mg loading dose followed by 40 mg every other week.
†Pause in therapy of 7–59 days.
‡Gap ≥60 days in index therapy.
¶ p < 0.001.
§ p < 0.01.
|| p < 0.05.
PsO = Psoriasis; PsA = Psoriatic arthritis; PsO/PsA = Both psoriasis and psoriatic arthritis.